The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Homocysteine and Dementia: An International Consensus Statement
Open accessAbstract
Identification of modifiable risk factors provides a crucial approach to the prevention of dementia. Nutritional or nutrient-dependent risk factors are especially important because dietary modifications or use of dietary supplements may lower the risk factor level. One such risk factor is a raised concentration of the biomarker plasma total homocysteine, which reflects the functional status of three B vitamins (folate, vitamins B12, B6). A group of experts reviewed literature evidence from the last 20 years. We here present a Consensus Statement, based on the Bradford Hill criteria, and conclude that elevated plasma total homocysteine is a modifiable risk factor for development of cognitive decline, dementia, and Alzheimer’s disease in older persons. In a variety of clinical studies, the relative risk of dementia in elderly people for moderately raised homocysteine (within the normal range) ranges from 1.15 to 2.5, and the Population Attributable risk ranges from 4.3 to 31%. Intervention trials in elderly with cognitive impairment show that homocysteine-lowering treatment with B vitamins markedly slows the rate of whole and regional brain atrophy and also slows cognitive decline. The findings are consistent with moderately raised plasma total homocysteine (>11 μmol/L), which is common in the elderly, being one of the causes of age-related cognitive decline and dementia. Thus, the public health significance of raised tHcy in the elderly should not be underestimated, since it is easy, inexpensive, and safe to treat with B vitamins. Further trials are needed to see whether B vitamin treatment will slow, or prevent, conversion to dementia in people at risk of cognitive decline or dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011613 · Cited by 3,237
Self-citationFolate, Vitamin B12, and Serum Total Homocysteine Levels in Confirmed Alzheimer Disease
Clarke, R., Smith, A. D., Jobst, K. A., Refsum, H., Sutton, L., & Ueland, P. M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.11.1449 · Cited by 1,408
Self-citationCausation and Causal Inference in Epidemiology
Rothman, K. J., & Greenland, S. (2005) · American Journal of Public Health · doi:10.2105/ajph.2004.059204 · Cited by 1,259
Facts and recommendations about total homocysteine determinations: an expert opinion
Refsum, H., Smith, A. D., Ueland, P. M., Nexo, E., Clarke, R., McPartlin, J., Johnston, C., Engbaek, F., Schneede, J., McPartlin, C., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.021634 · Cited by 1,056
Self-citationROTHMAN, K. J. (1976) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112335 · Cited by 776
Durga, J., van Boxtel, M. P., Schouten, E. G., Kok, F. J., Jolles, J., Katan, M. B., & Verhoef, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60109-3 · Cited by 758
Beydoun, M. A., Beydoun, H. A., Gamaldo, A. A., Teel, A., Zonderman, A. B., & Wang, Y. (2014) · BMC Public Health · doi:10.1186/1471-2458-14-643 · Cited by 671 · cited 4×
“[17] 5 cohorts on 4,412 subjects Elevated tHcy (variety of cut-offs: 14.”
BackgroundMethodResultInfluentialKruman, I. I., Kumaravel, T. S., Lohani, A., Pedersen, W. A., Cutler, R. G., Kruman, Y., Haughey, N., Lee, J., Evans, M., & Mattson, M. P. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01752.2002 · Cited by 643
Cited by
Nutrition and prevention of cognitive impairment
Scarmeas, N., Anastasiou, C. A., & Yannakoulia, M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30338-7 · Cited by 612
Calderón‐Ospina, C. A., & Nava‐Mesa, M. O. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13207 · Cited by 530
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Regulators of the transsulfuration pathway
Sbodio, J. I., Snyder, S. H., & Paul, B. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14446 · Cited by 377
Homocysteine – from disease biomarker to disease prevention
Smith, A. D., & Refsum, H. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13279 · Cited by 261
Self-citationOne-Carbon Metabolism: Pulling the Strings behind Aging and Neurodegeneration
Lionaki, E., Ploumi, C., & Tavernarakis, N. (2022) · Cells · doi:10.3390/cells11020214 · Cited by 110
Neuroprotective Roles of the Reverse Transsulfuration Pathway in Alzheimer’s Disease
Paul, B. D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.659402 · Cited by 42
Gallagher, D., Kiss, A., Lanctot, K. L., & Herrmann, N. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12331 · Cited by 34
Lin, H., Himali, J. J., Satizabal, C. L., Beiser, A. S., Levy, D., Benjamin, E. J., Gonzales, M. M., Ghosh, S., Vasan, R. S., Seshadri, S., et al. (2022) · Cells · doi:10.3390/cells11091506 · Cited by 20
Metadata
- Authors
- Smith, A. D., Refsum, H., Bottiglieri, T., Fenech, M., Hooshmand, B., McCaddon, A., Miller, J. W., Rosenberg, I. H., & Obeid, R.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-02-20
- Volume
- 62
- Issue
- 2
- Pages
- 561-570
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2789200606
- Cited by
- 360
- References
- 44
- FWCI
- 26.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.